©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Psychiatry. Jun 19, 2025; 15(6): 105409
Published online Jun 19, 2025. doi: 10.5498/wjp.v15.i6.105409
Published online Jun 19, 2025. doi: 10.5498/wjp.v15.i6.105409
Targeting muscarinic receptors in schizophrenia treatment: Novel antipsychotic xanomeline/trospium chloride
Ana V Pejčić, Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia
Author contributions: Pejčić AV was responsible for conception, design, literature search, formal analysis, drafting and editing of the manuscript, and approved the final manuscript. The author has read and approved the final manuscript.
Conflict-of-interest statement: Author declares no conflict of interests for this article.
Corresponding author: Ana V Pejčić, PhD, Assistant Professor, Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovića 69, Kragujevac 34000, Serbia. anapejcic201502@yahoo.com
Received: January 21, 2025
Revised: April 4, 2025
Accepted: May 13, 2025
Published online: June 19, 2025
Processing time: 128 Days and 16.2 Hours
Revised: April 4, 2025
Accepted: May 13, 2025
Published online: June 19, 2025
Processing time: 128 Days and 16.2 Hours
Core Tip
Core Tip: Xanomeline/trospium chloride is a potential new treatment option for a wide range of schizophrenia symptoms, offering a relatively favorable tolerability and safety profile. However, additional research is required to better understand its effectiveness and safety in real-world clinical practice, and to define its optimal role in managing this complex psychiatric disorder. As new evidence emerges, it is vital to evaluate it critically.